Votubia Articles
Novartis' Votubia cleared for non-cancerous kidney tumors in EU
5 November 2012
New uses of Cialis, Votubia, Galvus, Eucreas and Eliquis backed by CHMP, but not Qsiva
24 September 2012
EU approval for Janssen-Cilag’s Zytiga in prostate cancer and Novartis’ Votubia for SEGA
8 September 2011
EMA recommends Boehringer/Lilly’s Tradjenta, Novartis’ Votubia and Sigma-Tau’s Eurartesim; updates on pioglitazone
27 June 2011
US FDA approves Novartis Afinitor for SEGA, Forest’s Teflaro for CABP and Avanir’s Nuedexta for PBA
1 November 2010
Showing 1-6 of 6 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
